Yellow fever vaccine-associated viscerotropic disease: Current perspectives

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 3345-3353

  Thomas, Roger E ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Postvaccination severe adverse events; Systematic review; Viscerotropic disease; Yellow fever vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ARGENTINA; AUSTRALIA; BELGIUM; BRAZIL; CHINA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ECUADOR; FRANCE; GERMANY; HUMAN; IRELAND; NEW ZEALAND; PERU; PORTUGAL; REVIEW; SPAIN; UNITED KINGDOM; UNITED STATES; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE; ADVERSE EFFECTS; CHEMICALLY INDUCED; DEVELOPING COUNTRY; META ANALYSIS; MORTALITY; MULTIPLE ORGAN FAILURE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

DEVELOPING COUNTRIES; HUMANS; MULTIPLE ORGAN FAILURE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER VACCINE;

EID: 84991726487     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S99600     Document Type: Review

References (72)

1. Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol. 2015;64:160-173.
2. Quaresma JAS, Pagliari C, Medeiros DBA, Duarte MIS, Vasconcelos PFC. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol. 2013;23(5):305-318.
3. Jentes ES, Poumerol G, Gershman MD, et al; Informal WHO Working Group on Geographic Risk for Yellow Fever. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11(8):622-632.
4. Hill DR. Mapping the risk of yellow fever infection. Curr Infect Dis Rep. 2012;14(3):246-255.
5. Rogers DJ, Wilson AJ, Hay SI, Graham AJ. The global distribution of yellow fever and dengue. Adv Parasitol. 2006;62:181-220.
6. Beasley DW, McAuley AJ, Bente DA. Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral Res. 2015;115:48-70.
7. WHO Emerging and Other Communicable Diseases, 1998. District Guidelines for Yellow Fever Surveillance. Geneva: World Health Organization; 1998. [Report No: WHO/EPI/GEN/98.09].
8. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday September12, 2005. Vaccine. 2007;25(15):2758-2765.
9. Pugachev KV, Guirakhoo F, Ocran SW, et al. High fidelity of yellow fever virus RNA polymerase. J Virol. 2004;78(2):1032-1038.
10. Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow-fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31:5798-5805.
11. Lee LA, Franzel L, Atwell J, et al. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. Vaccine. 2013;31(suppl 2):B61-B72.
12. World Health Organization Regional Office for the Western Pacific Region. Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization. 2nd ed. Manila, Philippines: WHO Press; 2013.
13. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038-5058.
14. Whittembury A, Ramirez G, Hernández H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27(43):5974-5981.
15. Thomas RE, Jackson D. A database in ACCESS for assessing vaccne serious events. Vaccine. 2015;5:9-16.
16. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(6):e1000097.
17. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Tyler Williamson T. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf. 2011;6(3):145-154.
18. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011;29(28):4544-4555.
19. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. J Trop Med Hyg. 2012;86(2):359-372.
20. Biscayart C, Carrega MEP, Sagradini S, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266-1272.
21. DeSilva M, Sharma A, Staples E, Arndt B, Shieh W-J, Shames J. Fatal yellow fever vaccine-associated viscerotropic disease-Oregon, September 2014. MMWR Morb Mortal Wkly Rep. 2015;64(10):279-281.
22. Leung WS, Chan MC, Chik SH, Tsang TY. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong. J Travel Med. 2016;23(4):taw020.
23. Isenman H, Burns A. A case of yellow-fever associated disease. N Z Med J. 2012;125:92-95.
24. Fournier J-P, Bernardin G, Laffont C, et al. Vaccination anti amarile compliquée d’une primo infection grave par le virus de l’immunodeficience humaine (VIH 1): à propos d’une observation [Yellow fever vaccination complicated by a serious primary infection with HIV in connection with an observation]. Rétrovirus la Revue du Sida. 1989;2(4):154-156.
25. A Joint Statement of the US Public Health Service, North Carolina State Board of Health, Forsyth County Health Department and Bowman Gray School of Medicine. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA. 1966;198(6):671-672.
26. Bae H-G, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis. 2008;197(11):1577-1584.
27. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES. J Infect Dis. 2008;198(4):500-507.
28. Muñoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med. 2008;15(3):202-205.
29. Struchiner CJ, Luz PM, Dourado I, et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect. 2004;132(5):939-946.
30. Gerasimon G, Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J. 2005;98(6):653-656.
31. Douce RW, Freire D, Tello B, Vasquez GA. Case report: a case of yellow fever vaccine-associated viscerotropic disease in Ecuador. Am J Trop Med Hyg. 2010;82(4):740-742.
32. Kennedy CC, Mullon J. Yellow fever vaccine associated viscerotropic disease in a young woman: a rare complication of a common vaccine. Crit Care Med. 2007;35(12 suppl):A286.
33. Vasconcelos PFC, Luna EJ, Galler R, et al; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358(9276):91-97.
34. de Filippis AMB, Nogueira RMR, Jabor AV, et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17 DD vaccination during an outbreak of yellow fever in Brazil. Vaccine. 2004;22(9-10):1073-1078.
35. Levy S, Mullane K, Miller M, et al. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51(44):989-993.
36. Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine. 2007;25(50):8480-8485.
37. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358(9276):121-122.
38. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358(9276):98-104.
39. de Mello Vieira J, Sinari V, Vasconcelos Dias FV. Um caso de hepatite letal após vacinação anti-amarílica [A case of fatal hepatitis due to yellow fever vaccine]. J Soc Cienc Med Lisb. 1965;129:51-72. Portuguese.
40. Zhou Q. Adverse effects of attenuated yellow fever vaccine with multiple organ injury-a case report. Zhong Hua Yi Xue Za Zhi. 2005;85(13):936.
41. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. (Chap. 36). Philadelphia: Saunders/Elsevier; 2008:959-1056.
42. Monath TP. Short report: suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010;82(5):919-921.
43. Vellozzi C, Mitchell T, Miller E; Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteriod therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg. 2006;75(2):333-336.
44. Engel AR, Vasconcelos PFC, McArthur MA, Barrett ADT. Characterization of a viscerotropic yellow fever variant from a patient in Brazil. Vaccine. 2006;24:2803-2809.
45. O’Conghaile SO, Alsharbaty MJ, McDermott SR, Conlon PJ, Royston MD, Dwyer RC. Fulminant hepatitis and multisystem organ failure following yellow fever vaccination: description of a fatal case. Anaesth Intensive Care. 2014;42(3):423-424.
46. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22(17-18):2103-2105.
47. Adhiyaman V, Oke A, Cefal C. Effects of yellow fever vaccination. Lancet. 2001;358:1907-1908.
48. Appenzeller S, Faria AV, Zanardi VA, Fernandes SR, Costallat LTL, Cendes F. Vascular involvement of the central nervous system and systemic diseases: etiologies and MRI findings. Rheumatol Int. 2008;28(12):1129-1137.
49. Rowland M, Plackett TP, Smith R. Yellow fever vaccine-associated viscerotropic disease. Mil Med. 2012;177(4):467-469.
50. Troillet N, Laurencet F. Letter to the editor. Lancet. 2001;358:1908-1909.
51. Turpo G, Ticona M, Uchuya J, Whittembury A, Seligman SJ. Third case of fatal yellow fever vaccine-associated viscerotropic disease in a young Peruvian woman. Am J Trop Med Hyg. 2010;87(5 suppl 1):383. [Conference of the Annual Meeting of the Am Soc Trop Med Hyg, Atlanta, November 2012, Conf Pub 87(5 Suppl 1):383].
52. Van Langenberg ER. Acute necrosis of the liver. An unusual case. Lancet. 1944;243(6286):244-245.
53. Martins RDM, Maia MDLD, Santos EMD, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol. 2010;2(2):178-183.
54. Ministério do Saúde, Brasil. Boletim de Atualizaҫão-Dezembro/2009 [webpage on the Internet]. Emergências em Saúde Pública de Importância Nacional (ESPIN) de Febre Amarela Silvestre em São Paulo e no Rio Grande do Sul e a Situaҫão Epidemiólogica Atual no Brasil (2008/2009). Available from: http://portal.saude.gov.br. Accessed July 8, 2013.
55. Ministério do Saúde, Secretaria de Vigilancia em Saúde, Brasil [webpage on the Internet]. Oficina de Trabalho. Subsídios para Discussão e Redefinição da Estratégia de Vacinação Contra Febre Amarela No Brasil; 2009:22. Available from: http://portal.saude.gov.br. Accessed July 8, 2013.
56. Ministério do Saúde, Fundação Nacional de Saúde, Brasil [webpage on the Internet]. Eventos Adversos sérios Associados com a vacina 17D contra Febra Amarela; 2009:23. Available from: http://portal.saude.gov.br. Accessed July 8, 2013.
57. Romano AP, Costa ZG, Ramos DG, et al. Yellow fever outbreaks in unvaccinated populations, Brazil, 2008-2009. PLoS Negl Trop Dis. 2014;8(3):e2740.
58. Lawrence G, Menzies R, Burgess M, et al. Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun Dis Intell. 2003;27(3):307-323.
59. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell. 2004;28(2):244-248.
60. Khromava AY, Eidex RB, Weld LH, et al; Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256-3263.
61. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077-6082.
62. Nordin J, Parker ED, Vazquez-Benitez G, et al. Safety of the yellow fever vaccine: a retrospective study. J Travel Med. 2013;20(6):368-373.
63. van de Pol EM, Gisolf EH, Richter C. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands. J Travel Med. 2014;21(6):421-424.
64. WHO [webpage on the Internet]. International travel and health. Yellow Fever. Geneva: World Health Organization. Available from: http://www.who.int/ith/vaccines/yf/en/. Accessed May 24, 2016.
65. CDC [webpage on the Internet]. ACIP Yellow Fever Vaccine Recommendations. Available from: www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/yf.html. Accessed May 24, 2016.
66. Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccine. 2005;1(5):207-214.
67. Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001. Vaccine. 2010;28(24):4059-4064.
68. Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis. 2001;7(6):945-951.
69. Thomas RE, Lorenzetti DL, Spragins W. Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review. Am J Pub Health. 2013;103(3):e16-e29.
70. Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offitt PA, editors. Vaccines. 6th ed. (Chap. 38). Edinburgh: Elsevier/Saunders; 2013:870-968.
71. Seligman SJ. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis. 2011;17(10):1891-1893.
72. Miyaji KT, Luiz AM, Lara AN, et al. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years or more. Hum Vaccin Immunother. 2013;9(2):277-282.